{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["17(6)"],"submitter":["Lee A"],"pubmed_abstract":["Sotorasib (LUMAKRAS™ in the USA and LUMYKRAS™ in the EU) is an orally active, first-in-class G12C-mutant KRAS (KRAS<sup>G12C</sup>) inhibitor. By binding irreversibly to KRAS<sup>G12C</sup>, sotorasib inhibits downstream signalling pathways which are associated with cell growth and differentiation. Sotorasib is indicated for the treatment of adults with advanced, previously treated, KRAS G12C mutation-positive non-small cell lung cancer (NSCLC) in multiple countries, including the countries of the EU and the USA. A clinically relevant objective response rate was observed in patients with KRAS G12C mutation-positive NSCLC during the primary analysis and in an updated analysis of the phase I/II CodeBreaK 100 trial. Furthermore, a clinically relevant response duration was reported in updated analyses of the trial. Sotorasib has a manageable tolerability profile, with permitted dose modifications to manage toxicity. In summary, sotorasib is a promising KRAS<sup>G12C</sup> inhibitor that increases the available treatment options for patients with KRAS G12C mutation-positive NSCLC who were previously treated with platinum-based chemotherapy and/or immunotherapy."],"journal":["Targeted oncology"],"pagination":["727-733"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9715446"],"repository":["biostudies-literature"],"pubmed_title":["Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer."],"pmcid":["PMC9715446"],"pubmed_authors":["Lee A"],"additional_accession":[]},"is_claimable":false,"name":"Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.","description":"Sotorasib (LUMAKRAS™ in the USA and LUMYKRAS™ in the EU) is an orally active, first-in-class G12C-mutant KRAS (KRAS<sup>G12C</sup>) inhibitor. By binding irreversibly to KRAS<sup>G12C</sup>, sotorasib inhibits downstream signalling pathways which are associated with cell growth and differentiation. Sotorasib is indicated for the treatment of adults with advanced, previously treated, KRAS G12C mutation-positive non-small cell lung cancer (NSCLC) in multiple countries, including the countries of the EU and the USA. A clinically relevant objective response rate was observed in patients with KRAS G12C mutation-positive NSCLC during the primary analysis and in an updated analysis of the phase I/II CodeBreaK 100 trial. Furthermore, a clinically relevant response duration was reported in updated analyses of the trial. Sotorasib has a manageable tolerability profile, with permitted dose modifications to manage toxicity. In summary, sotorasib is a promising KRAS<sup>G12C</sup> inhibitor that increases the available treatment options for patients with KRAS G12C mutation-positive NSCLC who were previously treated with platinum-based chemotherapy and/or immunotherapy.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-04T13:46:33.677Z","creation":"2025-04-04T13:46:33.677Z"},"accession":"S-EPMC9715446","cross_references":{"pubmed":["36315377"],"doi":["10.1007/s11523-022-00922-w"]}}